Clinical Trials Logo

Neurodegenerative Diseases clinical trials

View clinical trials related to Neurodegenerative Diseases.

Filter by:

NCT ID: NCT02823158 Terminated - Parkinson Disease Clinical Trials

Bilateral Pallidal Stimulation in Patients With Advanced Parkinson's Disease-LATESTIM

LATESTIM
Start date: September 2016
Phase: N/A
Study type: Interventional

Deep brain stimulation (DBS) is an established treatment for advanced complicated Parkinson's disease (PD). Several controlled randomized studies have given proof of an advantage for operated patients as compared to medically treated patients in terms of motor outcome, activities of daily living and health status. However these studies have addressed mostly stimulation of the subthalamic nucleus (STN). GPi stimulation has not been compared to best medical treatment (BMT) in a prospective randomized controlled trial in patients with complicated PD who are not good candidates for STN stimulation. The investigators aim assessing GPi-DBS in patients with PD who have contraindications for STN-DBS.

NCT ID: NCT02802033 Active, not recruiting - Clinical trials for Degenerative Diseases, Spinal Cord

A Multicenter Prospective Registry for the Management of Degenerative Spine Disorders

Start date: January 2016
Phase:
Study type: Observational [Patient Registry]

Details regarding the degenerative spine disorders will be collected with a specific focus on the use of osteobiologics in treating degenerative conditions and their impact on fusion, as well as patient-reported outcomes for these conditions.

NCT ID: NCT02795052 Recruiting - Stroke Clinical Trials

Neurologic Stem Cell Treatment Study

NEST
Start date: June 2016
Phase: N/A
Study type: Interventional

This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http://mdstemcells.com/nest/

NCT ID: NCT02696603 Recruiting - Parkinson Disease Clinical Trials

Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)

mPower
Start date: March 2015
Phase: N/A
Study type: Interventional

The purpose of this study is to understand variation in the symptoms of Parkinson disease. This study uses an iPhone app to record these symptoms through questionnaires and sensors.

NCT ID: NCT02663531 Recruiting - Healthy Clinical Trials

Retinal Neuro-vascular Coupling in Patients With Neurodegenerative Disease

Start date: September 27, 2016
Phase: N/A
Study type: Interventional

Alzheimer´s disease (AD) in one of the most important causes of dementia and poses a considerable challenge in health care. Today, criteria for the diagnosis and the follow up of patients with AD mainly rely either on subjective tests or invasive methods. This limits the general applicability of the latter test for population screening and underlines the need for the identification of easily accessible tools for the identification of high-risk subjects. Because of its unique optical properties, the eye offers the possibility of the non-invasive assessment of both structural and functional alterations in neuronal tissue. As the neuro-retina is part of the brain, it does not come as a surprise that neuro-degenerative changes in the brain are accompanied by structural and possibly also functional changes in the neuro-retina and the ocular vasculature. The current study seeks to test the hypothesis that beside the known anatomical changes, also functional changes can be detected in the retina of patients with AD. For this purpose, flicker light induced hyperemia will be measured in the retina as a functional test to assess the coupling between neural activity and blood flow. Further, structural parameters such as retinal nerve fiber layer thickness and function parameters such as ocular blood flow and retinal oxygenation will be assessed and compared to age and sex matched controls.

NCT ID: NCT02656498 Completed - Clinical trials for Mild Cognitive Impairment

[18F]THK-5351 Positron Emission Computed Tomography Study of Normal, Mild Cognitive Impairment, Alzheimer's Disease and Other Neurodegenerative Disease

Start date: January 11, 2016
Phase: Phase 2
Study type: Interventional

This is a cross-sectional and longitudinal study to evaluate the clinical utility of [18F]THK-5351 positron emission computed tomography in cognitively healthy volunteers, mild cognitive impairment (MCI), Alzheimer's disease (AD) and other neurodegenerative patients.

NCT ID: NCT02452216 Completed - Brain Cancer Clinical Trials

Using Ferumoxytol-Enhanced MRI to Measure Inflammation in Patients With Brain Tumors or Other Conditions of the CNS

Start date: June 10, 2015
Phase: Early Phase 1
Study type: Interventional

This pilot clinical trial study will assess the inflammatory response of brain tumors or other central nervous system conditions in pediatric and adult patients using ferumoxytol-enhanced MRI. Imaging features will be correlated with the number of inflammatory cells (macrophages) at histopathology. Determining the extent of inflammation associated with pathologies in the central nervous system may be helpful for diagnostic and prognostic purposes as well as monitoring treatment response of current and future immunotherapies.

NCT ID: NCT02418546 Completed - Parkinson's Disease Clinical Trials

Electronic-health Application To Measure Outcomes REmotely Clinical Trial

EAT MORE
Start date: April 2015
Phase: N/A
Study type: Interventional

This is a phase II feasibility, safety, tolerability and preliminary efficacy study of an e-Health application versus in-person nutritional counseling to maintain or increase weight in patients with neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), Parkinson's Disease (PD) and Huntington's disease (HD). Primary Objectives include the feasibility, safety, tolerability and efficacy of an e-Health application to maintain or increase body weight compared to in-person nutritional counseling. Secondary Objectives are to measure the number of calories required to maintain or increase body weight in neurodegenerative diseases at all stages of the disease. Tertiary Objectives are to test the effects of an e-Health application compared to in-person nutritional counseling on disease progression using the ALSFRS-R, UHDRS or UDysRS, on survival, and on quality of life using the PROMIS SF v1.1 scale.

NCT ID: NCT02402426 Enrolling by invitation - Healthy Clinical Trials

Brain Health Registry: An Online Registry to Identify and Assess Subjects for Brain Research

BHR
Start date: September 2013
Phase:
Study type: Observational [Patient Registry]

The overall goal of this project is to identify, assess and longitudinally monitor subjects who are interested in participating in brain research. Participants will enroll through the website, BrainHealthRegistry.org, and provide informed consent prior to any study activities. The website will collect a variety of information, including participants' overall health, memory complaints, family history of dementia and Alzheimer's disease (AD), mood status, sleep, diet, and exercise-all through self-reported online questionnaires. Participants will also be ask to take online cognitive tests, and to return to the website at regular intervals, to complete follow-up questionnaires and neuropsychological assessments. Everyone over the age of 18 is welcome to participate. To join the Brain Health Registry, please visit www.BrainHealthRegistry.org.

NCT ID: NCT02288000 Recruiting - Alzheimer Disease Clinical Trials

Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases

WP3_P002
Start date: September 14, 2016
Phase: Phase 1
Study type: Interventional

The early assessment of new drugs for Alzheimer's disease remains difficult because of the lack of predictive end-point. The use of a battery including different parameters could improve this early development of new drugs. Nevertheless, the interest of such a battery should previously be validated with the yet marketed AD drugs.